| Project/Area Number |
21591350
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | University of Toyama |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ISHIKAWA Fumihiko 理化学研究所, 免疫アレルギー科学総合研究センター ヒト疾患モデル研究ユニット, ユニットリーダー (30403918)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 抗体産生不全症 / 自然免疫 / X連鎖無ガンマグロブリン血症 / Toll様受容体 / ブルトンチロシンキナーゼ |
|---|
| Research Abstract |
Approximately 15-20% of patients with X-linked agammaglobulinemia(XLA), which is caused by BTK deficiency, have neutropenia, and it is associated with the severity of infection. BTK-deficient neutrophils had more production of reactive oxygen species(ROS) after various stimuli, which was associated with more apoptosis. The production of ROS and apoptosis of BTK-deficient neutrophils were reversed by transduction of recombinant BTK. These data suggest that severe neutropenia in patients with XLA can be treated with recombinant BTK.
|
